Evaluation of multiple drug use in patients with type 2 diabetes mellitus

Basit Öğe Kaydı
dc.authoridinci, habibe/0000-0003-2883-259X
dc.contributor.authorInci, Habibe
dc.date.accessioned2024-09-29T15:54:43Z
dc.date.available2024-09-29T15:54:43Z
dc.date.issued2021
dc.departmentKarabük Üniversitesien_US
dc.description.abstractObjective Multiple drug use (Polypharmacy) is common in Diabetes Mellitus (DM) patients. The purpose of this study was to evaluate the presence of polypharmacy and comorbid conditions in patients with DM. Method The sociodemographic data, comorbidity diseases, and prescription records of 607 patients diagnosed with type 2 DM were retrospectively analyzed. Polypharmacy was defined as the use of five or more different drugs. Results The mean number of drugs used by the DM patients was 6.7 +/- 2.5. It was observed that 77.9% of the DM patients had polypharmacy. The mean number of drugs used by the patients in the polypharmacy group was 7.7 +/- 1.7. The most common comorbidities in DM patients were diseases of the musculoskeletal system. The use of drugs for musculoskeletal diseases and the number of drugs were statistically higher in female patients than in male patients. In the DM patients, polypharmacy was higher in the females, those older age, those having a longer history of DM disease, and those having a comorbid disease. Conclusion The total number of drugs used by the DM patients showed the presence of polypharmacy. Advanced age, long disease duration, female gender, and presence of comorbidities were predictive factors for polypharmacy in diabetic patients. Before starting additional medication for DM patients, it is necessary to pay attention to the interaction of the drugs to be used and to plan prescriptions considering the medications used by the patient continuously.en_US
dc.identifier.doi10.1007/s13340-021-00495-5
dc.identifier.endpage404en_US
dc.identifier.issn2190-1678
dc.identifier.issn2190-1686
dc.identifier.issue4en_US
dc.identifier.pmid34567922en_US
dc.identifier.scopus2-s2.0-85100525544en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage399en_US
dc.identifier.urihttps://doi.org/10.1007/s13340-021-00495-5
dc.identifier.urihttps://hdl.handle.net/20.500.14619/4233
dc.identifier.volume12en_US
dc.identifier.wosWOS:000615759700001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Japan Kken_US
dc.relation.ispartofDiabetology Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDiabetes mellitusen_US
dc.subjectPolypharmacyen_US
dc.subjectRisken_US
dc.subjectComorbid diseasesen_US
dc.titleEvaluation of multiple drug use in patients with type 2 diabetes mellitusen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu